Table 2 Number of significant adverse events in both groups with description of the events
From: A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis
Significant Adverse Events (SAEs) | Description of SAEs | HRG | LRG |
|---|---|---|---|
Cardiovascular events | NSTEMI | 2 | 0 |
CVA | 1 | 1 | |
Abdominal aortic aneurysm rupture | 0 | 1 | |
Total number of cardiovascular events | 3 | 2 | |
Thrombotic | Fistula thrombosis | 5 | 3 |
DVT and PE | 0 | 1 | |
Total number of thrombotic events | 5 | 4 | |
Sepsis | 17 | 10 | |
Metabolic bone complication | 1 | 1 | |
Miscellaneous | Blood transfusion | 1 | 0 |
Gastric ulcer | 1 | 0 | |
Skin lesions | 1 | 0 | |
Tumour | 1 | 1 | |
Transplant kidney pain | 0 | 1 | |
Sickle cell crisis | 0 | 1 | |
RTA with spinal injury | 0 | 1 | |
Non- cardiac | 0 | 1 | |
Total miscellaneous | 4 | 5 | |
Mortality | Sepsis | 4 | 0 |
Cardiovascular event | 3 | 1 | |
Sudden cardiac death | 2 | 1 | |
Total mortality | 9 | 2 | |
Total SAEs | 39 | 24 |